identifying unmet needs in relapsed/refractory mcl
Published 5 years ago • 81 plays • Length 4:06Download video MP4
Download video MP3
Similar videos
-
4:43
how to manage relapsed/refractory mcl - new agents and unmet needs
-
7:11
selection of a btk inhibitor in relapsed/refractory mcl
-
3:51
selecting therapy for relapsed/refractory mcl
-
3:31
nccn guidelines for relapsed/refractory mcl
-
5:32
relapsed/refractory dlbcl: unmet needs
-
14:03
clinical considerations for therapy selection in relapsed/refractory mcl
-
1:35
dr. lee on b-cell receptor targeting in relapsed/refractory mcl
-
1:20
dr. goy the evolution of treatment in relapsed/refractory mcl
-
3:46
battling relapsed diffuse large b-cell lymphoma (dlbcl) - sam's story
-
50:04
mantle cell lymphoma: from current treatments to future innovations(podcast)
-
43:47
relapsed and refractory hodgkin lymphoma
-
7:51
relapsed/refractory mantle cell lymphoma
-
1:36
dr. rule on long-term follow-up of ibrutinib monotherapy in relapsed/refractory mcl
-
1:18
dr. chaudhry on unmet needs in relapsed/refractory multiple myeloma
-
1:47
dr. leslie on the role of btk inhibitors in relapsed/refractory mcl
-
1:17
dr. costa on an unmet needs in relapsed/refractory multiple myeloma
-
1:11
dr. andreadis on car t-cell therapy in relapsed/refractory mcl
-
1:08
dr. gerson on updates in relapsed/refractory mcl
-
0:57
dr. kahl discusses unmet needs in mcl
-
1:08
dr. song on zanubrutinib activity in relapsed/refractory mcl
-
1:25
dr. lee on early efficacy data with cirmtuzumab/ibrutinib in relapsed/refractory mcl
-
1:04
dr. wang on the safety profile of brexucabtagene autoleucel in relapsed/refractory mcl